GiadaBianchiMD

PubMed

• Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
  Omar Nadeem, Michelle P Aranha, Robert Redd, Michael Timonian, Sophie Magidson
  Nature Communications. 2025-01-03
• 1 citations
  The dynamics of hematopoiesis over the human lifespan.
  Hojun Li, Parker Côté, Michael Kuoch, Jideofor Ezike, Katie Frenis
  Nature Methods. 2024-12-05
• Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
  Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
  Blood Advances. 2024-12-03

Abstracts/Posters

• Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma
  Giada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Giada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application
  Giada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
  Giada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma
  Giada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Special Symposium on ASH-Supported Researchers 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Special Symposium on ASH-Supported Researchers 
  60th American Society of Hematology Annual Meeting - 12/1/2018